Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Excelling at Discussion: Genuine Examples of overcoming adversity - 2The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- 3Police arrest 18 as anti-war protests spread across Tel Aviv, Haifa, Jerusalem
- 4South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry
- 5The 15 Most Rousing TED Chats on Self-awareness
- SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
- Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- How to track NASA’s Artemis II and Orion’s journey to the moon
- Plans for ‘stop anywhere’ night buses recommended by government for women’s safety
- Instructions to Warmly greet Certainty and Appeal
- Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- CDC pauses dozens of types of lab testing during evaluation and in wake of downsizing
- Lockheed Martin opens new hypersonic weapons facility
- Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
